First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX) : study protocol for a randomized controlled trial. / Grønhøj, Christian; Jensen, David Hebbelstrup; Glovinski, Peter Viktor; mpw981, mpw981; Jensen, Allan Bardow; Oliveri, Roberto Stefan; Specht, Lena; Thomsen, Carsten; Darkner, Sune; Kiss, Katalin; Fischer-Nielsen, Anne; von Buchwald, Christian.
In: Trials, Vol. 18, No. 1, 108, 2017.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX)
T2 - study protocol for a randomized controlled trial.
AU - Grønhøj, Christian
AU - Jensen, David Hebbelstrup
AU - Glovinski, Peter Viktor
AU - mpw981, mpw981
AU - Jensen, Allan Bardow
AU - Oliveri, Roberto Stefan
AU - Specht, Lena
AU - Thomsen, Carsten
AU - Darkner, Sune
AU - Kiss, Katalin
AU - Fischer-Nielsen, Anne
AU - von Buchwald, Christian
PY - 2017
Y1 - 2017
N2 - BackgroundSalivary gland hypofunction and xerostomia are major complications following radiotherapy for head and neck cancer and may lead to debilitating oral disorders and impaired quality of life. Currently, only symptomatic treatment is available. However, mesenchymal stem cell (MSC) therapy has shown promising results in preclinical studies. Objectives are to assess safety and efficacy in a first-in-man trial on adipose-derived MSC therapy (ASC) for radiation-induced xerostomia.MethodsThis is a single-center, phase I/II, randomized, placebo-controlled, double-blinded clinical trial. A total of 30 patients are randomized in a 1:1 ratio to receive ultrasound-guided, administered ASC or placebo to the submandibular glands. The primary outcome is change in unstimulated whole salivary flow rate. The secondary outcomes are safety, efficacy, change in quality of life, qualitative and quantitative measurements of saliva, as well as submandibular gland size, vascularization, fibrosis, and secretory tissue evaluation based on contrast-induced magnetic resonance imaging (MRI) and core-needle samples. The assessments are performed at baseline (1 month prior to treatment) and 1 and 4 months following investigational intervention.DiscussionThe trial is the first attempt to evaluate the safety and efficacy of adipose-derived MSCs (ASCs) in patients with radiation-induced xerostomia. The results may provide evidence for the effectiveness of ASC in patients with salivary gland hypofunction and xerostomia and deliver valuable information for the design of subsequent trials.
AB - BackgroundSalivary gland hypofunction and xerostomia are major complications following radiotherapy for head and neck cancer and may lead to debilitating oral disorders and impaired quality of life. Currently, only symptomatic treatment is available. However, mesenchymal stem cell (MSC) therapy has shown promising results in preclinical studies. Objectives are to assess safety and efficacy in a first-in-man trial on adipose-derived MSC therapy (ASC) for radiation-induced xerostomia.MethodsThis is a single-center, phase I/II, randomized, placebo-controlled, double-blinded clinical trial. A total of 30 patients are randomized in a 1:1 ratio to receive ultrasound-guided, administered ASC or placebo to the submandibular glands. The primary outcome is change in unstimulated whole salivary flow rate. The secondary outcomes are safety, efficacy, change in quality of life, qualitative and quantitative measurements of saliva, as well as submandibular gland size, vascularization, fibrosis, and secretory tissue evaluation based on contrast-induced magnetic resonance imaging (MRI) and core-needle samples. The assessments are performed at baseline (1 month prior to treatment) and 1 and 4 months following investigational intervention.DiscussionThe trial is the first attempt to evaluate the safety and efficacy of adipose-derived MSCs (ASCs) in patients with radiation-induced xerostomia. The results may provide evidence for the effectiveness of ASC in patients with salivary gland hypofunction and xerostomia and deliver valuable information for the design of subsequent trials.
U2 - 10.1186/s13063-017-1856-0
DO - 10.1186/s13063-017-1856-0
M3 - Journal article
C2 - 28270226
VL - 18
JO - Trials
JF - Trials
SN - 1745-6215
IS - 1
M1 - 108
ER -
ID: 174357769